Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy

Biology Direct

Claus O Wilke¹  Ahmad R Sedaghat² 

[1]Section of Integrative Biology, Center for Computational Biology and Bioinformatics, and Institute for Cell and Molecular Biology, The University of Texas at Austin, Austin, TX 78712, USA

[2]Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

关键词: IC50;    pharmacodynamics;    viral life cycle;    antiretroviral therapy;    HAART;    viral dynamics;    HIV;   

Others  :  797103
DOI  :  10.1186/1745-6150-6-42

 received in 2011-03-26, accepted in 2011-09-12,  发布年份 2011

【 摘 要 】

Background

More and more antiretroviral therapies are being developed for treatment of HIV infection. The in-vivo efficacy of these drugs is commonly predicted based on in-vitro measures of antiviral effect. One primary in-vitro measure is the IC50, the amount of drug required for 50% inhibition of viral replication. We have previously shown that HIV life-cycle kinetics impact clinically observed HIV viral dynamics. Here we present a mathematical model of how they affect the pharmacodynamics of antiretroviral drugs.

Results

We find that experimentally measured antiretroviral IC50s are determined by three factors (i) intrinsic drug properties (e.g. drug-target binding), (ii) kinetics of the HIV life cycle, and (iii) kinetics of drug-inhibited infected cells. Our model predicts that the IC50 is a declining function of the duration of the drug-susceptible stage in the host cell. We combine our model with known viral life-cycle kinetics to derive a measure of intrinsic properties, reflecting drug action, for known antiretroviral drugs from previously measured IC50s. We show that this measure of intrinsic drug property correlates very well with in vitro-measured antiviral activity, whereas experimentally measured IC50 does not.

Conclusions

Our results have implications for understanding pharmacodynamics of and improving activity of antiretroviral drugs. Our findings predict that drug activity can be improved through co-administration of synergistic drugs that delay the viral life cycle but are not inhibitory by themselves. Moreover, our results may easily extend to treatment of other pathogens.

This article was reviewed by Dr. Ruy Ribeiro, Dr. Ha Youn Lee, Dr. Alan Perelson and Dr. Christoph Adami.

【 授权许可】

   
2011 Sedaghat and Wilke; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA 2008, 300(5):555-570.
• [2]Dunning J, Nelson M: Novel strategies to treat antiretroviral-naive HIV-infected patients. J Antimicrob Chemother 2009, 64(4):674-679.
• [3]McKinnon JE, Mellors JW, Swindells S: Simplification strategies to reduce antiretroviral drug exposure: Progress and prospects. Antivir Ther 2009, 14(1):1-12.
• [4]Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, et al.: Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004, 78(4):1718-1729.
• [5]Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al.: Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14(7):762-766.
• [6]Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, et al.: Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 2009.
• [7]Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF: Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 2008, 105(12):4832-4837.
• [8]Sedaghat AR, Siliciano RF, Wilke CO: Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 2009, 14(2):263-271.
• [9]Chou TC: Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharm 1974, 10:235-247.
• [10]Atkins GL, Nimmo IA: Current trends in the estimation of michaelis-menten parameters. Anal Biochem 1980, 104(1):1-9.
• [11]Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, et al.: Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001, 194(12):1731-1741.
• [12]Rouzine IM, Sergeev RA, Glushtsov AI: Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci USA 2006, 103(3):666-671.
• [13]Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586.
• [14]Mittler JE, Markowitz M, Ho DD, Perelson AS: Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS 1999, 13(11):1415-1417.
• [15]Abbotts J, Jaju M, Wilson SH: Thermodynamics of A:G mismatch poly(dG) synthesis by human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 1991, 266(6):3937-3943.
• [16]Reddy B, Yin J: Quantitative intracellular kinetics of HIV type 1. AIDS Res Hum Retroviruses 1999, 15(3):273-283.
• [17]Wang J, Kondo N, Long Y, Iwamoto A, Matsuda Z: Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins. J Virol Methods 2009, 161(2):216-222.
• [18]Stebbing J, Gazzard B, Douek DC: Where does HIV live? N Engl J Med 2004, 350(18):1872-1880.
• [19]Stevenson M: HIV-1 pathogenesis. Nat Med 2003, 9(7):853-860.
• [20]Douek DC, Picker LJ, Koup RA: T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003, 21:265-304.
• [21]Spivak A, Rabi A, McMahon M, Siliciano RF: Understanding decay of viremia in patients on raltegravir. Conference on Retroviruses and Opportunistic Infections (552) 2009.
• [22]Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, et al.: Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002, 76(17):8518-8531.
• [23]Carroll SS, Stahlhut M, Geib J, Olsen DB: Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs. J Biol Chem 1994, 269(51):32351-32357.
• [24]Markgren PO, Schaal W, Hamalainen M, Karlen A, Hallberg A, et al.: Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem 2002, 45(25):5430-5439.
• [25]Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44(4):920-928.
• [26]Ferguson NM, Fraser C, Anderson RM: Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency. Trends Pharmacol Sci 2001, 22(2):97-100.
• [27]McMahon MA, Shen L, Siliciano RF: New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009, 22(6):574-582.
• [28]Gao WY, Zhou BS, Johns DG, Mitsuya H, Yen Y: Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine. Biochem Pharmacol 1998, 56(1):105-112.
• [29]Fumero E, Podzamczer D: New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect 2003, 9(11):1077-1084.
• [30]Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO: Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009, 83(10):4884-4894.
• [31]Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, et al.: In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol 2009, 81(2):211-216.
• [32]Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000, 25(2):99-102.
• [33]Snyder S, D'Argenio DZ, Weislow O, Bilello JA, Drusano GL: The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000, 44(4):1051-1058.